an employee benefit could be life-changing
Beating cancer starts with knowing you have it
The earlier cancer is found, the higher the chance everyone wins: likely better outcomes for those finding it and greater peace of mind for those without it. Offering Galleri®, a multi-cancer early detection test, was found to encourage employees to join, stay, and understand they’re part of a workplace that truly cares.1
Introducing the Galleri test
The Galleri test is a groundbreaking and potentially life-changing advancement in cancer detection for adults with an elevated risk for cancer, such as those aged 50 or older.
With the Galleri test, employees could receive the benefits of early detection of multiple cancers through a simple blood draw.
including cancers employees aren’t routinely screened for today9,10
0.5% false-positive rate
to help minimize unnecessary medical procedures9
in predicting the location of the cancer, directing diagnostic workup9
Speak with our team about offering the Galleri® test as an employee benefit
We look forward to speaking with you soon.
Important Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “No Cancer Signal Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory / Test Information
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
Sign up for email
Sign up below to receive the latest news on the Galleri test, relevant information and helpful resources for employee benefits decision makers.
Thank you for signing up to learn more about the Galleri® test.
Let us know if you’d also like to speak with our team directly about offering the Galleri® test as an employee benefit.
- Market research data on file 2020. Study demographics included 314 respondents, age 40+, who were employed full-time at larger organizations.
- Vrinten C, McGregor LM, Heinrich M, von Wagner C, Waller J, Wardle J, Black GB. What do people fear about cancer? A systematic review and meta-synthesis of cancer fears in the general population. Psycho-Oncology. 2017 Aug;26(8):1070 – 1079.
- Screening includes methods with USPSTF A or B rating. SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2017 Sub. Includes persons aged 50+ diagnosed 2006 – 2015.
- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50 – 79 diagnosed 2006 – 2015. “Early/Localized” includes invasive localized tumors that have not spread beyond organ of origin. “Late/Distant Metastases” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.
- Based on stage II and stage IV breast, colorectal, and lung cancer, and metastatic/non-metastatic pancreatic cancer.
- Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, et al. Medical Care Costs Associated With Cancer in Integrated Delivery Systems. J Natl Compr Canc Netw. 2018;16(4):402 – 10.
- DaCosta Byfield S, Nash Smyth E, Mytelka D, et al. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population. J Med Econ. 2013;16(12):1379 – 86.
- American Cancer Society. Lifetime Risk of Developing or Dying From Cancer. [updated 2020 Jan 13; cited 2021 Feb 18]. Available from: https://www.cancer.org/healthy…
- Klein E, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test. Oral presentation at: American Association for Cancer Research; April, 2021; LB013.
- The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to routine screening tests your healthcare provider recommends.